• News

    News

2019 has been an exciting one for us at BioAscent and this month GEN – Genetic Engineering & Biotechnology News, published a profile about BioAscent that captured our story so far - a fitting way to round off the year.

This year has seen new partnerships, government minister visits, team growth and an expansion into the US market. We have taken time to reflect on all that has been achieved this year.

A successful year

We were delighted to announce a three-fold increase in our revenues during 2018 and with projections on-track for a further 2-fold increase in 2019. This year ends with four times the resource than at the start of 2018, with a team of 40 members of staff, and we have successfully combined our existing compound management business with highly experienced chemistry and biology teams with a significant track record of drug discovery success.  We continue to build the team with high calibre and well-respected scientists to meet the growing demand for our services. Find out more about our growth here.

Expanding into the US market

To support the growing international demand for our integrated drug discovery services, we appointed Julian Abery as Director of Business Development, North America in Autumn this year to spearhead our US expansion. Find out more.

MSP visits

This year we welcomed members of the Scottish Parliament, Ivan McKee MSP (Minister of Trade, Investment and Innovation) and Graham Simpson MSP (Deputy Convener), to our site. During the visits we showcased our biology, chemistry and state-of-the-art compound management and library facilities so that they could see first-hand the great work our team are doing.

Dr Phil Jones’ career journey podcast

Dr Phil Jones talked about his career on the ‘Careers in Discovery’ podcast. He discussed the importance of becoming an expert in this field; why having good people around you is vital; how the role of the chemist is changing and the crucial role of networking and interacting with different kinds of people to expand knowledge. You can listen to the podcast here.

New Partnerships

2019 has been a year of forging partnerships, alliances and collaborations:

European Lead Factory

In May we announced that we had been chosen as partner for the European Lead Factory’s ESCulab (European Screening Centre: unique library for attractive biology) project to push towards the transformation of potential drug targets to new medicines. Over the next five years, the European Lead Factory will initiate 185 new drug discovery projects. Find out more.

Medicines Discovery Catapult

We have collaborated with the Medicines Discovery Catapult to harness the power of AI and machine learning to focus compound collections. To find out more, you can read the case study on the collaboration here. BioAscent was also selected as one of the world-class CRO partners tasked with delivering support to the Medicines Discovery Catapult’s Virtual R&D Discovery Services platform. Read more here.

Heriot-Watt University

We collaborated with scientists at Heriot-Watt University to find a molecule that could be used to stop heart stents failing. Each year, thousands of people in the UK have stents permanently inserted into their arteries to keep blood flowing and treat the underlying cause of coronary heart disease however, 5% of patients have artery walls damaged causing inflammation in the process, meaning several thousand patients have to be readmitted annually. Find out more about the work being done to reduce the failure of stents.

Huntington’s promising leads identified using compound cloud library

Our unique on-demand compound library, Compound Cloud, has been used by the ALBORADA Drug Discovery Institute for virtual screening and to progress promising leads against a novel Huntington’s disease target. Find out more here.

PAINS article published in Drug Discovery World

We recently published an article in Drug Discovery World, a quarterly review of drug discovery and development, voicing opinions of some of the industry’s leading experts. The article, written by Dr Philip Jones and Dr Stuart McElroy, is titled ‘Reducing the PAINS in high throughput screening: assay design as a toll for maximising efficiency.’ You can download the full article here.

Welcoming an intern

In June we welcomed Kirsty Tinto, a Pharmacology student at the University of Strathclyde, as part of the Scot Grad Life Sciences Internship Programme. It was fantastic to work with a leading Scottish university to promote opportunities for young graduates. You can read more about Kirsty’s internship experience here.

PhD student welcomed back to BioAscent

George Pandarakalam has been welcomed back to BioAscent as a Senior Scientist in its Biology team. George worked on an assay development project at the European Screening Centre (now BioAscent) back in 2015 and 2016. His work during that time has now been published in a recent  paper alongside BioAscent’s Director of Biosciences, Dr Stuart McElroy, published in the International Journal of Parasitology: Drugs and Drug Resistance. To read more, click here.

Events

We attended a whole host of events throughout the year all across the world including (but not limited to) exhibiting at SLAS 2019 in Washington, poster presentation at the NovAliX conference in Cannes, attended the EFMC-ACSMEDI MedChem Frontiers Symposium in Krakow, and exhibited at ELRIG Drug Discovery in Liverpool and Discovery on Target in Boston, to name a few. These events have been a great way to get the word out about all our services, as well as the perfect opportunity to catch-up with clients and make new, long lasting contacts. Our events schedule is on the website, so you can find out where we will be in 2020.

Thank you for all your support throughout the year and look forward to working with you in 2020.

 

Get In Touch

Let's talk about how we can maximise your drug discovery success.

Contact

Director of Chemistry

Dr Angus Morrison

Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he was Medicinal Chemistry lead of the European Lead Factory project responsible for over 30 hit to leads programmes.  Prior to this Angus has held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology. During his time in pre-clinical drug discovery he has had broad exposure and experience of working across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination.  Angus has a PhD in Organic Chemistry from Strathclyde University and carried out Postgraduate studies at Cambridge University. He is a co-author on over 30 papers and patents.

Director of Chemistry

Dr Angus Morrison

Angus has over 15 years’ experience as a practising medicinal chemist leading both project and medicinal chemistry delivery in multinational and multidisciplinary teams.  In his most recent role as Head of Chemistry at the European Screening Centre Newhouse he was Medicinal Chemistry lead of the European Lead Factory project responsible for over 30 hit to leads programmes.  Prior to this Angus has held leadership roles at Organon, Schering-Plough, MSD, Prosidion and Redx Oncology. During his time in pre-clinical drug discovery he has had broad exposure and experience of working across a diverse range of therapeutic areas and target classes from hit generation to candidate nomination.  Angus has a PhD in Organic Chemistry from Strathclyde University and carried out Postgraduate studies at Cambridge University. He is a co-author on over 30 papers and patents..

Dr David Milroy

David is a Partner at Maven Capital Partners where he is a member of Maven’s Investment Committee and is responsible for sourcing and executing private equity investments in Scotland as well as technology and life science investments across the UK. His current investments include Blacktrace Group, Curo Compensation, Optoscribe, QikServe, CB Technology and BioAscent. David started his career as a scientist with GlaxoSmithKline.

After completing his PhD, he moved to international consultancy firm Wood Mackenzie (and then parent Deutsche Bank) where he supported the healthcare banking team, advising clients on their corporate and licensing strategies; and performing due diligence projects on companies, products and technologies.

David joined Aberdeen Asset Management’s private equity division (spun-out to form Maven in 2009) in September 2007 as Fund Manager for an early-stage technology fund. David has a First Class Honours degree in Pharmacy, a PhD (Molecular Biology/Gene Delivery) from the University of Bath and a MBA from The University of Edinburgh.

CEO BioCity

Dr Glenn Crocker MBE DPhil

Glenn Crocker is an experienced CEO, company founder, non-executive director and investor in the life sciences sector. He has been CEO of BioCity Group since mid-2003, shortly after it was founded. He has a DPhil in Immunology from Oxford University and qualified as a chartered accountant with EY, focussing on working with biotech companies in Palo Alto, California and Cambridge, UK, where he headed up the UK Biotech practice for EY.

BioCity builds, funds and grows life science companies at its four incubator sites in the UK.

Glenn is a non-executive director of a number of companies and consults on business incubation, start-up creation and cluster growth. He has been directly involved in investing in life science companies through BioCity’s own or managed funds since 2006.

In 2014 Glenn received an MBE for services to the biotechnology industry.

Dr Louis J. Nisbet D.Sc. - Vivanova Ltd

Dr Louis Nisbet

Louis began his career in pharmaceuticals R&D with Roche, Glaxo and SmithKline during which period he achieved international recognition in the discovery of NCEs in infectious diseases. He was one of the UK’s first biotechnology entrepreneurs establishing Xenova and Brax both of which achieved successful exits via IPO and trade sale respectively.

He was the first recipient of the Ernst & Young Biotechnology Entrepreneur of the Year Award. Since 2000 he has been active in investing and building businesses in the private and public equity markets across the health sector. Venture capital investments have been with Kurma Partners, Sitka Partners, Noble Group and Alderley Park Ventures.

He has considerable executive and non-executive Board experience with over 20 quoted and private companies. He has a Ph.D. from Imperial College, London and D.Sc. from the U of Strathclyde.

Chief Commercial Officer

Dr Mike Piper

Mike is an experienced life sciences professional with a track record in sales and marketing strategy, general management, licensing and contract negotiation.  Mike was formerly Head of Sales and Marketing at CXR Biosciences, an investigative toxicology CRO. Following CXR’s acquisition by Concept Life Sciences in 2015 he became Vice President Business Development Safety & Toxicology.  Prior to his time at CXR, Mike worked in business development and licensing at the specialty pharmaceutical company Ardana plc, and held various pharmaceutical industry management consultancy roles at ZS Associates, Deloitte and Arthur Andersen Business Consulting.  Mike has a PhD in genomics from the University of Cambridge, MRC Laboratory of Molecular Biology.

Chief Scientific Officer

Dr Phil Jones

Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council at Schering-Plough. Numerous clinical candidates resulted from groups for which he was responsible. These span a broad range of target families and therapeutic areas. He has led the European Screening Centre team at Biocity Scotland, Newhouse for the past 5 years and this group plays a key role in delivering validated hit series for SMEs and academics through the IMI funded European Lead Factory. Phil’s postgraduate studies were carried out at the University of Manchester and Imperial College. Phil was elected a Fellow of the Royal Society of Chemistry in 2005, he chaired the Medicinal Chemistry interest group of the Royal Society of Chemistry for 8 years, chaired the organising committee of the European Federation of Medicinal Chemistry – International Symposium on Medicinal Chemistry (EFMC-ISMC) in 2016 and sat on the Executive Committee of the EFMC for four years. He is a co-author on over 70 scientific papers and patents.

Chief Scientific Officer

Dr Phil Jones

Phil has over 30 years medicinal chemistry and drug discovery experience from Roche, Organon, Schering-Plough, Merck and the University of Dundee including senior roles as Executive Director and Acting Site Head. He was a member of the Research Leadership Council at Schering-Plough. Numerous clinical candidates resulted from groups for which he was responsible. These span a broad range of target families and therapeutic areas. He has led the European Screening Centre team at Biocity Scotland, Newhouse for the past 5 years and this group plays a key role in delivering validated hit series for SMEs and academics through the IMI funded European Lead Factory. Phil’s postgraduate studies were carried out at the University of Manchester and Imperial College. Phil was elected a Fellow of the Royal Society of Chemistry in 2005, he chaired the Medicinal Chemistry interest group of the Royal Society of Chemistry for 8 years, chaired the organising committee of the European Federation of Medicinal Chemistry – International Symposium on Medicinal Chemistry (EFMC-ISMC) in 2016 and sat on the Executive Committee of the EFMC for four years. He is a co-author on over 70 scientific papers and patents.

Director of Biosciences

Dr Stuart McElroy

With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Throughout the 5 years of the European Lead Factory project he held the position of Head of Biology at the European Screening Centre (ESC), leading a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Prior to this Stuart helped establish the Dundee Drug Discovery Unit (DDU) where he spent 7 years as a project and then team leader working across a wide array of novel drug targets and assays. He also had a leading operational role in DDU-Industry partnerships with both large pharma and SMEs.

Director of Biosciences

Dr Stuart McElroy

With over 12 years working in drug discovery Stuart has extensive experience of developing and trouble-shooting novel screening assays, designing screening cascades, compound screening, hit validation and supporting hit to lead and lead optimisation programs. Throughout the 5 years of the European Lead Factory project he held the position of Head of Biology at the European Screening Centre (ESC), leading a team of bioscientists in prosecuting and triaging the output of over 90 high throughput screens across all major target classes and disease indications. Prior to this Stuart helped establish the Dundee Drug Discovery Unit (DDU) where he spent 7 years as a project and then team leader working across a wide array of novel drug targets and assays. He also had a leading operational role in DDU-Industry partnerships with both large pharma and SMEs.

Chief Operating Officer and Co-founder

Dr Sylviane Boucharens

Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent Sylviane was Head of Global Compound repository and in-vitro Screening (Merck Sharp & Dohme, Newhouse Scotland). She was also responsible for managing a portfolio of early Drug Discovery projects in Cardiovascular from Target Identification and validation to Lead Optimisation. Sylviane attained her PhD in Cellular and Molecular Biology from the University Joseph Fourier, Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, France and University of Manchester, UK under the Wellcome Trust International Fellowship.

Chief Operating Officer and Co-founder

Dr Sylviane Boucharens

Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent Sylviane was Head of Global Compound repository and in-vitro Screening (Merck Sharp & Dohme, Newhouse Scotland). She was also responsible for managing a portfolio of early Drug Discovery projects in Cardiovascular from Target Identification and validation to Lead Optimisation. Sylviane attained her PhD in Cellular and Molecular Biology from the University Joseph Fourier, Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, France and University of Manchester, UK under the Wellcome Trust International Fellowship.

Chief Operating Officer and Co-founder

Dr Sylviane Boucharens

Sylviane has more than 20 years’ experience in scientific research and drug discovery environment. Sylviane has a track record in building and leading outstanding and productive teams into seamless successful enterprises in start-up and medium and large pharma environment. Prior to BioAscent Sylviane was Head of Global Compound repository and in-vitro Screening (Merck Sharp & Dohme, Newhouse Scotland). She was also responsible for managing a portfolio of early Drug Discovery projects in Cardiovascular from Target Identification and validation to Lead Optimisation. Sylviane attained her PhD in Cellular and Molecular Biology from the University Joseph Fourier, Grenoble, France, followed by post-doctoral positions at the INSERM U366 Laboratory, France and University of Manchester, UK under the Wellcome Trust International Fellowship.

Ian McDonald

Ian is a Chartered Accountant and an experienced Finance Director/Chief Financial Officer with a successful track record gained in SMEs and PLCs in the manufacturing and customer service industries - particularly within life sciences, pharmaceuticals and FMCG.  

Ian has successful record of achievement as a CFO within Private Equity backed businesses with credibility gained from developing positive and effective relationships with stakeholders, and successful participation in exits with a proven track record in securing funding for growth from both public sector finance providers as well as institutional finance providers. 

Ian’s career is varied having worked primarily in the UK but with extensive overseas travel. As well as heading up a number of large finance teams Ian’s experience extends to successfully evaluating  and commercially shaping high value projects including worldwide ERP system implementations as well as mergers and acquisition experience.

Chief Executive Officer

Paul Smith

An experienced Senior Executive with both General Management and Business Development experience in the pharmaceutical/CRO arena. Paul has an understanding of the drug development process from discovery to clinical research gained through more than 29 years in the CRO/pharmaceutical sector. A strategic thinker and management professional with experience gained in both small and large companies and with recent start-up experience including leading  funding discussions with VCs and other corporate finance groups. Paul recently turned around and sold CXR Biosciences to Concept Lifesciences in late 2015. Elected Fellow of the Royal Society of Biology, 2013.

Chief Executive Officer

Paul Smith

An experienced Senior Executive with both General Management and Business Development experience in the pharmaceutical/CRO arena. Paul has an understanding of the drug development process from discovery to clinical research gained through more than 29 years in the CRO/pharmaceutical sector. A strategic thinker and management professional with experience gained in both small and large companies and with recent start-up experience including leading  funding discussions with VCs and other corporate finance groups. Paul recently turned around and sold CXR Biosciences to Concept Lifesciences in late 2015. Elected Fellow of the Royal Society of Biology, 2013.